A Phase 3 interventional study of Early Discharge with Lasix® ONYU (furosemide injection, for subcutaneous use) using SQIN-Infusor in Heart Failure and Acute Decompensated Heart Failure, sponsored by University of Texas Southwestern Medical Center. Not yet recruiting at 2 sites in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by University of Texas Southwestern Medical Center · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing furosemide in Heart Failure — 5 open to participants now, 5 under way, 1 of them phase 3. Furosemide · Heart Failure.
Among the 36 studies testing furosemide in Heart Failure, this one is the 7th largest by planned enrollment of the 35 interventional ones that give a count, is the only one that started in 2028, is one of 6 in phase 3, and was the 35th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →5 of the 36 studies testing furosemide in Heart Failure are open now, in 2 countries. Recruiting first, the newest first:
Lakeland Regional Health Systems, Inc. · Sites in United States
Ages 18+
University of Florida · Sites in United States
Ages 18–80
Copenhagen University Hospital, Rigshospitalet · Sites in Denmark
Ages 18+
Heart Center Research, LLC · Sites in United States
Ages 19+
By country, each count listing its studies:
Furosemide: first FDA approval 1966 (LASIX), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 7 · Phase 4 17
First in 2000; this study’s year is marked. 1 started in 2028.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 42 across the 35 interventional studies. Of the 23 that completed or were terminated, 9 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 36 have an industry lead sponsor. The 10 most frequent:
University of Texas Southwestern Medical Center is the lead sponsor of 1,012 studies on the registry; 200 are open to participants now.
Of its 139 completed or terminated interventional studies of FDA-regulated products, 105 (76%) have results posted.
22 studies in Heart Failure by University of Texas Southwestern Medical Center: 7 open now, 7 under way, 2 of them phase 3. Of 12 finished, 3 (25%) have results posted.
Among the 22 studies in Heart Failure by University of Texas Southwestern Medical Center, this one is the 6th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2028, is one of 2 in phase 3, and was the 21st registered.
University of Texas Southwestern Medical Center’s Heart Failure studies by the year they started, since 2003.
3 of the studies testing furosemide in Heart Failure that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06979726University of FloridaGator SCALES-WHF: SubCutaneous Administration of Lasix to Eliminate Symptoms of Worsening Heart Failure | 2026-11-30 |
| NCT05276219Copenhagen University Hospital, RigshospitaletDECONGEST-AHF: Vasodilatation or Loop Diuretics in Acute Heart Failure | 2027-05-01 |
| NCT07263035Lakeland Regional Health Systems, Inc.Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure | 2027-06-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 36 studies testing furosemide in Heart Failure, from their registry updates:
Among University of Texas Southwestern Medical Center’s 22 in Heart Failure:
This tab as a report to print or save as PDF → With an account.
This will be a prospective, cluster-randomized, crossover, non-inferiority trial of 250 participants within 48 hours of an inpatient admission for heart failure or emergency department presentation for heart failure with plans for admission or observation/short-stay hospitalization comparing early discharge using subcutaneous furosemide to standard inpatient care. Individual practice groups will serve as "clusters" and the unit of randomization. Each participating cluster will implement either the early discharge strategy using the intervention or standard care for initial two-month blocks, followed by a crossover to the alternate strategy. The primary outcome is days alive and out of hospital at 30 days.
HF contributes to over 1 million emergency department visits and nearly 1 million hospitalizations annually. The estimated annual mean cost per person with HF was $32,955 in 2017-2018, with the majority of costs due to hospitalization. The current standard of care typically involves admission for intravenous (IV) diuretics, monitoring for adequate decongestion, transition to oral diuretics, and discharge once clinical stability is achieved. The median length of stay for HF hospitalizations in the United States is 5 days but varies significantly across health systems and at the patient level. Extended hospitalizations, while traditionally considered necessary for complete decongestion, carry substantial risks, including increased risk of all-cause death and readmission. Patients experience deconditioning and increased frailty and are at risk for hospital-acquired complications, including infections, falls, and cognitive decline. Furthermore, prolonged hospitalization can lead to post-hospital syndrome, characterized by increased vulnerability and risk for adverse events in the immediate post-discharge period. For these reasons, reducing length of stay has emerged as a critical goal in HF management, aimed at both decreasing costs and improving patient outcomes by minimizing hospital-related complications and preserving quality of life.
Recent developments in subcutaneous furosemide formulations offer a potential solution to this clinical challenge. Pharmacokinetic studies demonstrate that subcutaneous furosemide achieves bioavailability comparable to IV administration and superior to oral formulations. The consistent absorption profile and reliable bioavailability of subcutaneous furosemide, combined with its ease of administration, presents an opportunity to provide hospital-level diuresis in the outpatient setting. This could enable earlier discharge while maintaining the intensity of diuretic therapy needed for complete decongestion. However, a critical knowledge gap exists regarding the safety and efficacy of an early discharge strategy utilizing subcutaneous furosemide compared to traditional inpatient management.
This trial aims to address this knowledge gap through a cluster-randomized crossover study comparing early discharge with subcutaneous furosemide to standard inpatient care and receipt of IV furosemide. By implementing standardized protocols across two major health systems, the investigators will evaluate whether this novel approach can safely reduce length of stay while maintaining clinical outcomes. The study design accounts for institutional variations in care delivery while providing robust data on safety, efficacy, and resource utilization. Results from this trial could fundamentally change the management paradigm for acute heart failure hospitalizations, potentially improving both healthcare efficiency and patient outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The practice group randomized to early discharge with subcutaneous furosemide home infusion will begin initiation of subcutaneous furosemide (LASIX-ONYU) with a SQIN-Infusor device prior to discharge from the hospital. Dosing will be based on pre-admission oral furosemide requirements. Those with a home dose of ≤80mg/day oral furosemide will receive 80mg subcutaneous once daily at home and those with \>80mg/day oral furosemide will receive 80mg subcutaneous twice daily at home.
Combination Product: Early Discharge with Lasix® ONYU (furosemide injection, for subcutaneous use) using SQIN-Infusor
Usual inpatient care with IV furosemide. Discharge timing determined by treating physician per standard practice.
Drug page: FurosemideStudies of FurosemideFurosemide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Each practice group randomized to early discharge with subcutaneous furosemide will provide the patient with prefilled units of Lasix® ONYU furosemide injection containing 80 mg per 2.67 mL in a single-dose prefilled cartridge co-packaged with a single-use Disposable Unit of the Infusor that will be used in conjunction with the reusable unit of the Lasix ONYU Infusor. Dosing based on pre-admission oral furosemide requirements: ≤80mg/day oral furosemide will be given 80mg subcutaneous once daily or \>80mg/day oral furosemide will be given 80mg subcutaneous twice daily. Dosing will be continued until clinical euvolemia is reached.
Also known as: subcutaneous furosemide
Days alive and out of the hospital
Days alive and out of the hospital will be ascertained via retrospective review of the electronic health record.
Time frame: 30-day
Change in Quality of Life
Longitudinal analysis of Kansas City Cardiomyopathy Overall Summary Scores
Time frame: Baseline, 14-day, and 30-day. The Kansas City Cardiomyopathy Questionnaire Overall Summary Score ranges from 0-100, where 0 is worst quality of life and 100 is best quality of life.
Change in N-terminal pro B-type natriuretic peptide
Longitudinal analysis of N-terminal pro B-type natriuretic peptide (NT-proBNP) levels
Time frame: Baseline, 14-day, and 30-day
Time-to-event for mortality and readmission
Time-to-event analyses for mortality and readmission outcomes
Time frame: 30-day
Plan to share: No
Start is estimated for Aug 2028; primary completion for Sep 2028, 1 month later.
Of 87 non-industry phase 3 interventional studies under Heart Failure, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 1 month is below that.
Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: start Aug 2026 → Aug 2028 and primary completion Aug 2028 → Sep 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Furosemide
University of Texas Southwestern Medical Center →